SYRS - Syros Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SYRS price evolution
SYRS
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $81.08 | $85.64 | $141.65 | |
| Short term investments | $24.78 | |||
| Net receivables | ||||
| Inventory | ||||
| Total current assets | $63.93 | $84.92 | $112.2 | $144.98 |
| Long term investments | ||||
| Property, plant & equipment | $17.58 | $18.22 | $18.86 | $19.48 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $21.8 | $22.53 | $23.19 | |
| Total investments | $24.78 | |||
| Total assets | $85 | $106.72 | $134.73 | $168.17 |
| Current liabilities | ||||
| Accounts payable | $9.65 | $7.47 | $11.35 | $11.54 |
| Deferred revenue | ||||
| Short long term debt | $2.5 | $14.08 | $8.99 | |
| Total current liabilities | $28.39 | $24.52 | $37.3 | $36.68 |
| Long term debt | $41.08 | $58.17 | $47.59 | $53.08 |
| Total noncurrent liabilities | $88.55 | $82.37 | $114.83 | |
| Total debt | $60.66 | $61.67 | $62.08 | |
| Total liabilities | $96.12 | $113.07 | $119.67 | $151.51 |
| Shareholders' equity | ||||
| Retained earnings | -$756.24 | -$749.84 | -$726.51 | -$722.81 |
| Other shareholder equity | ||||
| Total shareholder equity | -$6.35 | $15.06 | $16.66 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $141.65 | $170.55 | $95.39 | $173.98 |
| Short term investments | $34.84 | $38.07 | ||
| Net receivables | $1.69 | $2.98 | $2.3 | |
| Inventory | ||||
| Total current assets | $144.98 | $211.39 | $136.59 | $178.6 |
| Long term investments | $13.04 | $3.09 | ||
| Property, plant & equipment | $19.48 | $24.66 | $27.29 | $29.6 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $23.19 | $33.09 | $46.35 | $34.69 |
| Total investments | $34.84 | $51.1 | $3.09 | |
| Total assets | $168.17 | $244.49 | $182.94 | $213.3 |
| Current liabilities | ||||
| Accounts payable | $11.54 | $6.41 | $3.69 | $3.6 |
| Deferred revenue | $4.33 | $10.18 | $22.09 | |
| Short long term debt | $8.99 | $2.07 | $2.01 | $1.73 |
| Total current liabilities | $36.68 | $30.78 | $31.51 | $28.6 |
| Long term debt | $53.08 | $40.65 | $40.32 | $39.9 |
| Total noncurrent liabilities | $114.83 | $85.97 | $66.21 | $94.07 |
| Total debt | $62.08 | $63.57 | $65.19 | $66.21 |
| Total liabilities | $151.51 | $116.75 | $97.72 | $122.7 |
| Shareholders' equity | ||||
| Retained earnings | -$722.81 | -$558.23 | -$463.58 | -$377 |
| Other shareholder equity | $0.1 | -$0.08 | ||
| Total shareholder equity | $16.66 | $127.74 | $85.22 | $90.55 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.39 | |||
| Cost of revenue | ||||
| Gross Profit | $0.39 | |||
| Operating activities | ||||
| Research & development | $21.95 | $24.66 | $21.5 | |
| Selling, general & administrative | $5.46 | $6.27 | $5.89 | |
| Total operating expenses | $27.42 | $30.92 | $27.53 | |
| Operating income | -$27.42 | -$30.92 | -$27.14 | |
| Income from continuing operations | ||||
| EBIT | -$21.95 | -$2.4 | -$63.05 | |
| Income tax expense | ||||
| Interest expense | $1.38 | $1.31 | $1.33 | |
| Net income | ||||
| Net income | -$23.33 | -$3.71 | -$64.38 | |
| Income (for common shares) | -$23.33 | -$3.71 | -$64.38 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $9.94 | $14.88 | $23.49 | $15.09 |
| Cost of revenue | ||||
| Gross Profit | $9.94 | $14.88 | $23.49 | $15.09 |
| Operating activities | ||||
| Research & development | $108.15 | $111.94 | $99.87 | $76.06 |
| Selling, general & administrative | $28.28 | $29.3 | $23.04 | $21.32 |
| Total operating expenses | $138.92 | $150.75 | $122.91 | $97.39 |
| Operating income | -$128.99 | -$135.87 | -$99.42 | -$82.3 |
| Income from continuing operations | ||||
| EBIT | -$159.45 | -$90.52 | -$82.65 | -$82.25 |
| Income tax expense | ||||
| Interest expense | $5.13 | $4.13 | $3.91 | $1.79 |
| Net income | ||||
| Net income | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| Income (for common shares) | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$23.33 | -$3.71 | -$64.38 | |
| Operating activities | ||||
| Depreciation | $0.33 | $0.33 | $0.35 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $1.8 | $2.1 | $1.72 | |
| Total cash flows from operations | -$29.67 | -$31.1 | -$18.56 | |
| Investing activities | ||||
| Capital expenditures | $0.1 | $0.03 | $1.52 | |
| Investments | $24.97 | -$24.67 | ||
| Total cash flows from investing | $0.43 | $25.07 | -$24.64 | $1.52 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.12 | $43.38 | ||
| Net borrowings | -$0 | |||
| Total cash flows from financing | -$0.22 | $0.04 | -$0.27 | $43.38 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$81.25 | -$4.56 | -$56 | $26.34 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$164.57 | -$94.65 | -$86.56 | -$84.04 |
| Operating activities | ||||
| Depreciation | $2.33 | $2.97 | $3.02 | $2.77 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $10.43 | $11.41 | $10.35 | $10.94 |
| Total cash flows from operations | -$109.71 | -$123.06 | -$99.54 | -$57.36 |
| Investing activities | ||||
| Capital expenditures | $1.29 | -$1.24 | -$1.25 | -$3.34 |
| Investments | $36.05 | $68.43 | -$51.41 | $50 |
| Total cash flows from investing | $37.34 | $67.19 | -$52.65 | $46.66 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $43.53 | $119.9 | $70.82 | $103.78 |
| Net borrowings | -$0.07 | -$0.59 | -$0.27 | $39.38 |
| Total cash flows from financing | $43.46 | $131.04 | $70.51 | $142.95 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$28.91 | $75.17 | -$81.68 | $132.25 |
News
Fundamentals
| Market cap | $6.04M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 26.83M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 9.09 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 2.25 |
| Quick ratio | N/A |